UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

Goswami, P; Oliva, EN; Ionova, T; Else, R; Kell, J; Fielding, AK; Jennings, DM; ... Salek, S; + view all (2020) Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Frontiers in Pharmacology , 11 , Article 1308. 10.3389/fphar.2020.01308. Green open access

[thumbnail of fphar-11-01308.pdf]
Preview
Text
fphar-11-01308.pdf - Published Version

Download (645kB) | Preview

Abstract

Background: Validity is the ability of an instrument to measure what it claims to measure. It means the degree to which the empirical evidence supports the trustworthiness of interpretations based on the calculated scores. The hematological malignancy (HM) specific patient reported outcome measure (HM-PRO), is a newly developed instrument for use in daily clinical practice as well as in research. This study, provides the evidence for construct validity of the HM-PRO, specifically focusing on the convergent and divergent validity compared to the other established instruments used in hematology. Methods: This validation study adopted a prospective cross-sectional design where a heterogeneous group of patients diagnosed with different HMs and different disease state were recruited. A total of 905 patients were recruited from seven secondary care hospitals in the UK and online through five patient organizations. Patients were asked to complete the HM-PRO and other cancer specific PRO’s, FACT-G and EORTC QLQ C-30. Data analysis was performed using IBM SPSS 23 statistical software. Results: A total of 486 males (53.7%) and 419 females (46.3%), with a mean age of 64.3 (± 12.4) years and mean time since diagnosis of 4.6 (± 5.2) were recruited. The total score of Part A of the HM-PRO highly correlated with the five functional scales of the EORTC QLQ-C30 (Physical = −0.71, Role = −0.72, Emotional = −0.64, Cognitive = −0.58, Social = −0.74—p < 0.001). With respect to correlation with FACT-G, the total score of Part A of the HM-PRO highly correlated with Physical (−0.74), Emotional (−0.57), Functional (−0.66) domains and overall score of FACT-G (−0.74). Similarly, the total score of Part B of the HM-PRO highly correlated with three symptoms scales of EORTC QLQ-C30 (Fatigue scale = −0.74, Nausea and Vomiting = −0.52, Pain = −0.59—p < 0.001) and individual symptom items (Dyspnea = 0.51, Insomnia= 0.43, Appetite loss = 0.54—p < 0.001). Conclusion: The construct validity evidence presented in this research is a testimony to the HM-PRO’s ability to measure HRQoL issues which it intends to measure. This is of utmost importance when a PRO is used in routine clinical practice so that the interpretation of the scores or response to an individual item is understood by the clinicians/nurses as intended by the patients.

Type: Article
Title: Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
Open access status: An open access version is available from UCL Discovery
DOI: 10.3389/fphar.2020.01308
Publisher version: https://doi.org/10.3389/fphar.2020.01308
Language: English
Additional information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: hematological malignancy, HM-PRO, quality of life, symptoms, construct validity, clinical practice, clinical research
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10112189
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item